GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » ROCE %

EV Biologics (EV Biologics) ROCE % : -25.16% (As of Dec. 2017)


View and export this data going back to 2015. Start your Free Trial

What is EV Biologics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. EV Biologics's annualized ROCE % for the quarter that ended in Dec. 2017 was -25.16%.


EV Biologics ROCE % Historical Data

The historical data trend for EV Biologics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics ROCE % Chart

EV Biologics Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17
ROCE %
32.28 30.38 25.07 -168.04 -86.64

EV Biologics Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17 Dec17
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -575.65 -101.66 -2,673.33 - -25.16

EV Biologics ROCE % Calculation

EV Biologics's annualized ROCE % for the fiscal year that ended in Jun. 2017 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2017 )  (A: Jun. 2016 )(A: Jun. 2017 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2017 )  (A: Jun. 2016 )(A: Jun. 2017 )
=-6.504/( ( (36.443 - 25.149) + (33.278 - 29.559) )/ 2 )
=-6.504/( (11.294+3.719)/ 2 )
=-6.504/7.5065
=-86.64 %

EV Biologics's ROCE % of for the quarter that ended in Dec. 2017 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2017 )  (Q: Jun. 2017 )(Q: Dec. 2017 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2017 )  (Q: Jun. 2017 )(Q: Dec. 2017 )
=-5.78/( ( (33.278 - 29.559) + (58.954 - 16.719) )/ 2 )
=-5.78/( ( 3.719 + 42.235 )/ 2 )
=-5.78/22.977
=-25.16 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2017) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EV Biologics  (OTCPK:YECO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


EV Biologics ROCE % Related Terms

Thank you for viewing the detailed overview of EV Biologics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


EV Biologics (EV Biologics) Business Description

Traded in Other Exchanges
N/A
Address
1621 Central Avenue, Cheyenne, WY, USA, 82001
EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.
Executives
Daniel S Mckinney director, 10 percent owner, officer: CEO TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan director C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3

EV Biologics (EV Biologics) Headlines

From GuruFocus

EV Biologics Updates on NFT Warrant Dividend Distribution

By ACCESSWIRE ACCESSWIRE 08-30-2021

EV Biologics Briefs Shareholders on Market Cap Peer Comparison

By ACCESSWIRE ACCESSWIRE 08-12-2021

EV Biologics Generates Mesenchymal Stem Cell Lines

By ACCESSWIRE ACCESSWIRE 02-21-2023

EV Biologics Updates on NFT Minting

By ACCESSWIRE ACCESSWIRE 09-28-2021

EV Biologics Updates on FINRA Filings

By ACCESSWIRE ACCESSWIRE 03-09-2022

EV Biologics Unveils NFT Dividend Warrant

By ACCESSWIRE ACCESSWIRE 07-26-2021

EV Biologics NFT Dividend Information

By ACCESSWIRE ACCESSWIRE 08-09-2021